Can localised 19F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response?
McIntyre, Dominick J. O., Howe, Franklyn A., Ladroue, Christophe, Lofts, Fiona, Stubbs, Marion and Griffiths, John R.. (2011) Can localised 19F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response? Cancer Chemotherapy and Pharmacology, Vol.68 (No.1). pp. 29-36. ISSN 0344-5704
WRAP_Lofts_fulltext.pdf - Published Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Official URL: http://dx.doi.org/10.1007/s00280-010-1438-2
Background 5-Fluorouracil remains widely used in colorectal cancer treatment more than 40 years after its development. 19F magnetic resonance spectroscopy can be used in vivo to measure 5FU’s half-life and metabolism to cytotoxic fluoronucleotides. Previous studies have shown better survival associated with longer 5FU tumour half-life. This work investigated 5FU pharmacokinetics in liver metastases of colorectal cancer. Methods A total of 32 subjects with colorectal cancer undergoing 5FU treatment, 15 of whom had liver metastases, were examined in a 1.5T MRI scanner, using a large coil positioned over the liver. Non-localised spectra were acquired in 1-min blocks for 32 min after injection of a 5FU bolus. The 5FU half-life was measured in each subject, and averaged spectra were examined for the presence of fluoronucleotides. Associations with progression-free survival were assessed. Results No association was observed between 5FU halflife, tumour burden and survival. Half-lives were all shorter than those associated with improved survival in the literature. Remarkably, in the group with liver metastases, high levels of fluoronucleotides were associated with poorer survival; this counterintuitive result may be due to the higher levels of fluoronucleotides (whose level is higher in tumour tissue than in normal liver) in patients with higher tumour burdens. Conclusions It is recommended that future studies use chemical shift imaging at higher field strengths to better resolve tumour from normal liver. Non-localised spectroscopy retains prognostic potential by enabling straightforward detection of fluoronucleotides, which are present at very low concentrations distributed throughout the tissue.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)|
|Divisions:||Faculty of Science > Statistics|
|Library of Congress Subject Headings (LCSH):||Colon (Anatomy) -- Cancer -- Treatment, Rectum -- Cancer -- Treatment, Fluorouracil, Metastasis|
|Journal or Publication Title:||Cancer Chemotherapy and Pharmacology|
|Page Range:||pp. 29-36|
|Access rights to Published version:||Open Access|
|Funder:||University of Cambridge, Cancer Research UK (CRUK), Hutchison Whampoa Ltd.|
|References:||1. Segal NH, Saltz LB (2009) Evolving treatment of advanced colon cancer. Annu Rev Med 60:207–219 2. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner RR (1994) Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 343:1184–1187 3. Findlay MPN, Raynaud F, Cunningham D, Iveson A, Collins DJ, Leach MO (1996) Measurement of plasma 5-fluorouracil by highperformance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-a. Ann Oncol 7:47–53 4. Wolf W, Presant CA, Servis KL, El-Tahtawy A, Albright MJ, Barker PB, Ring R III, Atkinson D, Ong R, King M, Singh M, Ray M, Wiseman C, Blayney D, Shani J (1990) Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proceedings of the National Academy of Sciences 87:492–496 5. Wolf W, Waluch V, Presant CA (1998) Non-invasive F-19- NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed 11:380–387 6. Wolf W, Presant CA, Waluch V (2000) 19F-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Rev 41:55–74 7. Kamm YJL, Heerschap A, van den Bergh EJ, Wagener DJT (2004) 19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. Anti-Cancer Drugs 15:229–233 8. van Laarhoven HWM, Klomp DWJ, Rijpkema M, Kamm YLM, Wagener DJT, Barentsz JO, Punt CJA, Heerschap A (2007) Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed 20:128–140 9. Stevens AN, Morris PG, Iles RA, Sheldon PW, Griffiths JR (1984) 5-fluorouracil metabolism monitored in vivo by 19F NMR. Br J Cancer 50:113–117 10. McSheehy PMJ, Robinson SP, Ojugo ASE, Aboagye EO, Cannell MB, Leach MO, Judson IR, Griffiths JR (1998) Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo. Cancer Res 58:1185–1194 11. Sijens PE, Huang Y, Baldwin NJ, Ng TC (1991) 19F Magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine rif-1 tumors and liver. Cancer Res 51:1384–1390 12. McSheehy PM, Prior MJ, Griffiths JR (1989) Prediction of 5- fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo. Br J Cancer 60:303–309 13. Doi Y, Shimmura T, Kuribayashi H, Tanaka Y, Kanazawa Y (2009) Quantitative 19F imaging of nmol-level F-nucleotides/- sides from 5-FU with T2 mapping in mice at 9.4T. Magn Reson Med 62:1129–1139 14. Findlay MP, Leach MO (1994) In vivo monitoring of fluoropyrimidine metabolites: magnetic resonance spectroscopy in the evaluation of 5-fluorouracil. Anti-Cancer Drugs 5:260–280 15. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, Graveron-Demilly D (2001) Java-based graphical user interface for the MRUI quantitation package. MAGMA 12:141–152 16. Vanhamme L, van den Boogaart A, Van Huffel S (1997) Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129:35–43 17. Kamm YJL, Heerschap A, Wagener DJT (2000) Effect of carbogen breathing on the pharmacodynamics of 5-fluorouracil in a murine colon carcinoma. Eur J Cancer 36:1180–1186 18. Griffiths JR, McIntyre DJO, Howe FA, McSheehy PMJ, Ojugo ASE, Rodrigues LM, Wadsworth P, Price NM, Lofts F, Nicholson G, Smid K, Noordhuis P, Peters GJ, Stubbs M (2001) Issues of normal tissue toxicity in patient and animal studies— Effect of carbogen breathing in rats after 5-fluorouracil treatment. Acta Oncol 40:609–614 19. Ojugo ASE, McSheehy PMJ, Stubbs M, Alder G, Bashford CL, Maxwell RJ, Leach MO, Judson IR, Griffiths JR (1998) Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br J Cancer 77:873–879 20. Guerquin-Kern J-L, Leteurtre F, Croisy A, Lhoste J-M (1991) pH Dependence of 5-fluorouracil uptake observed by in vivo 31p and 19f nuclear magnetic resonance spectroscopy. Cancer Res 51:5770–5773 21. Howe FA, Robinson SP, Rodrigues LM, Griffiths JR (1999) Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing. Magn Reson Imaging 17:1307–1318 22. Honess DJ, Bleehen NM (1995) Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined. Br J Cancer 71:1175–1180 23. Gupta N, Saleem A, Kotz B, Osman S, Aboagye EO, Phillips R, Vernon C, Wasan H, Jones T, Hoskin PJ, Price PM (2006) Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res 12:3115–3123 24. van Laarhoven HWM, Gambarota G, Lok J, Lammens M, Kamm YLM, Wagener T, Punt CJA, van der Kogelz AJ, Heerschap A (2006) Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure. Neoplasia 8:477–487 25. van Laarhoven HWM, Klomp DWJ, Kamm YJL, Punt CJA, Heerschap A (2003) In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 tesla field strength. Cancer Res 63:7609–7612 26. Klomp DWJ, van Laarhoven HWM, Scheenen T, Kamm YJL, Heerschap A (2007) Quantitative 19F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver. NMR Biomed 20:485–492|
Actions (login required)